Y-mabs announces naxitamab chemoimmunotherapy investigational trial for high-risk neuroblastoma meets primary endpoint

New york, may 26, 2022 (globe newswire) --  y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that dr. shakeel modak, md from memorial sloan kettering (“msk”) will present results from the naxitamab-based chemoimmunotherapy trial in patients with chemoresistant high-risk neuroblastoma (“hr-nb”), at the american society of clinical oncology (“asco”) annual meeting to be held june 3-7, 2022.
YMAB Ratings Summary
YMAB Quant Ranking